Diabetes & Endocrinology Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

This Phase 3 trial is testing a once-weekly medication called eloralintide for adults who have obesity or are overweight, along with type 2 diabetes and an increased risk of heart problems. If successful, this treatment could help reduce both body weight and blood sugar levels, which may lower the chances of heart disease. The study plans to include 3000 participants from several countries but has not yet started recruiting.

INfluenza VaccInation To Mitigate typE 1 Diabetes

This Phase 4 study is exploring whether getting a flu vaccine can help preserve insulin-producing cells in people recently diagnosed with type 1 diabetes. The goal is to slow down the disease’s progression and help maintain insulin production longer. The trial is currently recruiting 100 participants in Denmark.

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

This Phase 4 trial is investigating how cholesterol-lowering treatments affect blood cells and blood vessel health in adults with type 1 diabetes. Since heart and blood vessel problems are common in type 1 diabetes, this research could lead to better ways to reduce cardiovascular risks and improve overall health. The study is recruiting 125 participants in the United States.

Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes

This Phase 3 trial is testing Stem Cell Educator therapy, which aims to improve the immune system and insulin production in people with type 1 diabetes. The therapy works by "educating" a patient’s immune cells, potentially offering a new approach beyond daily insulin injections. The study is active but not recruiting and is taking place at one location in the United States.

Mechanisms of Weight Loss: Tirzepatide vs Semaglutide

This Phase 4 trial compares two injectable medications, tirzepatide and semaglutide, to see which one better influences energy use and weight loss in adults with obesity. Understanding these effects may help improve treatment choices for managing weight. The study is recruiting in Canada and involves 12 weeks of treatment with detailed health assessments.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.